← Browse by Condition
Medical Condition
met amplification
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT07322783 Phase 2
Recruiting
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Enrollment
60 pts
Location
China
Sponsor
Qingdao Central Hospital
NCT05800340 Phase 2
Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Enrollment
30 pts
Location
China
Sponsor
Guangdong Provincial People's ...